Vše

Co hledáte?

Vše
Projekty
Výsledky výzkumu
Subjekty

Rychlé hledání

  • Projekty podpořené TA ČR
  • Významné projekty
  • Projekty s nejvyšší státní podporou
  • Aktuálně běžící projekty

Chytré vyhledávání

  • Takto najdu konkrétní +slovo
  • Takto z výsledků -slovo zcela vynechám
  • “Takto můžu najít celou frázi”

Survival in Kidney and Bladder Cancers in Four Nordic Countries through a Half Century

Identifikátory výsledku

  • Kód výsledku v IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11140%2F23%3A10467841" target="_blank" >RIV/00216208:11140/23:10467841 - isvavai.cz</a>

  • Výsledek na webu

    <a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=a0SbQ8tT9Q" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=a0SbQ8tT9Q</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.3390/cancers15102782" target="_blank" >10.3390/cancers15102782</a>

Alternativní jazyky

  • Jazyk výsledku

    angličtina

  • Název v původním jazyce

    Survival in Kidney and Bladder Cancers in Four Nordic Countries through a Half Century

  • Popis výsledku v původním jazyce

    Simple Summary: Cancers in the urinary bladder and kidney are common in men and rarer in women. Cigarette smoking is a shared risk factor for both of these cancers. Some 50 years ago, survival in these cancers was low, and it was worse for kidney than bladder cancer. In the present study, we could show improvement in survival for these cancers in the Nordic countries, and similar improvements have also been observed in other countries. Kidney cancer survival improved remarkably well, as 50 years ago, only 20-30% of the patients survived 5 years, but currently, some 75% survive 5 years. In male bladder cancer, 5-year survival is still somewhat better than survival in kidney cancer, but female kidney cancer survival has caught up with that of bladder cancer. The reasons for this positive development for both of these cancers is earlier diagnosis as patients with blood in urine are readily taken for examinations. Additionally, treatment has become more efficient, and continuously new medications are being introduced. Kidney and bladder cancers share etiology and relatively good recent survival, but long-term studies are rare. We analyzed survival for these cancers in Denmark, Finland, Norway (NO), and Sweden (SE) over a 50-year period (1971-2020). Relative 1- and 5-year survival data were obtained from the NORDCAN database, and we additionally calculated conditional 5/1-year survival. In 2016-2020, 5-year survivals for male kidney (79.0%) and bladder (81.6%) cancers were best in SE. For female kidney cancer, NO survival reached 80.0%, and for bladder cancer, SE survival reached 76.1%. The magnitude of 5-year survival improvements during the 50-year period in kidney cancer was over 40% units; for bladder cancer, the improvement was over 20% units. Survival in bladder cancer was worse for women than for men, particularly in year 1. In both cancers, deaths in the first year were approximately as many as in the subsequent 4 years. We could document an impressive development for kidney cancer with tripled male and doubled female 5-year survival in 50 years. Additionally, for bladder cancer, a steady improvement was recorded. The current challenges are to curb early mortality and target treatment to reduce long-term mortality.

  • Název v anglickém jazyce

    Survival in Kidney and Bladder Cancers in Four Nordic Countries through a Half Century

  • Popis výsledku anglicky

    Simple Summary: Cancers in the urinary bladder and kidney are common in men and rarer in women. Cigarette smoking is a shared risk factor for both of these cancers. Some 50 years ago, survival in these cancers was low, and it was worse for kidney than bladder cancer. In the present study, we could show improvement in survival for these cancers in the Nordic countries, and similar improvements have also been observed in other countries. Kidney cancer survival improved remarkably well, as 50 years ago, only 20-30% of the patients survived 5 years, but currently, some 75% survive 5 years. In male bladder cancer, 5-year survival is still somewhat better than survival in kidney cancer, but female kidney cancer survival has caught up with that of bladder cancer. The reasons for this positive development for both of these cancers is earlier diagnosis as patients with blood in urine are readily taken for examinations. Additionally, treatment has become more efficient, and continuously new medications are being introduced. Kidney and bladder cancers share etiology and relatively good recent survival, but long-term studies are rare. We analyzed survival for these cancers in Denmark, Finland, Norway (NO), and Sweden (SE) over a 50-year period (1971-2020). Relative 1- and 5-year survival data were obtained from the NORDCAN database, and we additionally calculated conditional 5/1-year survival. In 2016-2020, 5-year survivals for male kidney (79.0%) and bladder (81.6%) cancers were best in SE. For female kidney cancer, NO survival reached 80.0%, and for bladder cancer, SE survival reached 76.1%. The magnitude of 5-year survival improvements during the 50-year period in kidney cancer was over 40% units; for bladder cancer, the improvement was over 20% units. Survival in bladder cancer was worse for women than for men, particularly in year 1. In both cancers, deaths in the first year were approximately as many as in the subsequent 4 years. We could document an impressive development for kidney cancer with tripled male and doubled female 5-year survival in 50 years. Additionally, for bladder cancer, a steady improvement was recorded. The current challenges are to curb early mortality and target treatment to reduce long-term mortality.

Klasifikace

  • Druh

    J<sub>imp</sub> - Článek v periodiku v databázi Web of Science

  • CEP obor

  • OECD FORD obor

    30204 - Oncology

Návaznosti výsledku

  • Projekt

    <a href="/cs/project/LX22NPO5102" target="_blank" >LX22NPO5102: Národní ústav pro výzkum rakoviny</a><br>

  • Návaznosti

    P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Ostatní

  • Rok uplatnění

    2023

  • Kód důvěrnosti údajů

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Údaje specifické pro druh výsledku

  • Název periodika

    Cancers

  • ISSN

    2072-6694

  • e-ISSN

    2072-6694

  • Svazek periodika

    15

  • Číslo periodika v rámci svazku

    10

  • Stát vydavatele periodika

    CH - Švýcarská konfederace

  • Počet stran výsledku

    12

  • Strana od-do

    2782

  • Kód UT WoS článku

    000997031900001

  • EID výsledku v databázi Scopus

    2-s2.0-85160846611